EMCM is actively involved in the development of innovative biomaterials which bring together our knowledge in working with collagen molecules & human allografts to provide controlled drug and peptide release profiles via the aforementioned carriers. Our knowledge of working with hydrogels and combinations with the grafts add quite a significant value. This development is being tried across various platforms of controlled release & combinations in the pursuit of opening up new opportunities.

This method in development and subsequent products will benefit from the benefits in safety, cleanliness and mildness that the eCOO Technology offers in tissue processing, which EMCM continues to explore following its policy of constant innovation.

Due to host material, scientific and technical limitations, all advantages of the eCOO Technology platform may not be applicable to each product under eTiss, eColl & eNova products.